| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3270131 | HPB | 2010 | 9 Pages |
Abstract
An invasive component measuring >2Â cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Olivier Turrini, Joshua A. Waters, Thomas Schnelldorfer, Keith D. Lillemoe, Constantin T. Yiannoutsos, Michael B. Farnell, Michael G. Sarr, C. Max Schmidt,